Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early vs Delayed Heparin for VTE Prophylaxis in Hypertensive Intracerebral Hemorrhage
NCT06753786Recruiting
- Sponsor
- Pirogov Russian National Research Medical University
- Start
- Oct 2024
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Randomised trial of heparin in venous thromboembolism (VTE), pulmonary embolism (PE) and deep vein thrombosis (DVT) (2 arms), sponsored by Pirogov Russian National Research Medical University. Primary endpoints: Number of participants with acute venous thrombosis established using ultrasound examination up to 6 months, Number of participants with pulmonary embolism established using CT pulmonary angiogram up to 6 months and 4 more. Started Oct 2024; status: recruiting.
02
Drugs
heparin
03
Conditions
venous thromboembolism (VTE)pulmonary embolism (PE)deep vein thrombosis (DVT)
Beyond the preview
Go deeper on NCT06753786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06753786.